In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InfraReDx: Saved by Angels (and a VC)

Executive Summary

A rare combination of angels and the sole interested VC brought InfraReDx back from failure's door in search of a new way to identify the biggest mystery behind heart attacks--vulnerable plaque.
Advertisement

Related Content

InfraReDx’s Long Road To Commercialization Continues With Latest Financing
On The Hunt For Vulnerable Plaque InfraReDx Improves Stenting Safety
Prescient Medical's Dual Approach to Vulnerable Plaque
FoxHollow/Merck R&D Deal: The Value of Plaque
Volcano's Second Act
Volcano's Second Act
FoxHollow/Merck R&D Deal: The Value of Plaque
Vulnerable Plaque: Medical Device's New Biological Frontier
Vulnerable Plaque Heats Up
The Unstable State of Plaque Detection

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel